News

Video

Future Directions in Chronic GvHD

Author(s):

Preet M. Chaudhary, MD, PhDNoah Merin, MD, PhD

Dr. Chaudhary and Dr. Merin discuss potential areas for exploration and unmet needs in the chronic GvHD treatment landscape.

Related Videos
Lakshmi Nayak, MD
John Burke, MD
Timothy Hughes, MD, MBBS, FRACP, FRCPA
Ben Levy, MD, and Yan Leyfman, MD
BTK Inhibitors in CLL : Second Generation Drugs and Beyond
Carrie L. Kitko, MD
Lori A. Leslie, MD
Lori A. Leslie, MD
Changchun Deng, MD, PhD
Guenther Koehne, MD, PhD
Related Content
Kathleen A. Dorritie, MD, of University of Pittsburgh Medical Center Hillman Cancer Center​
June 11th 2024

Long-Term Data for Up-Front Combinations Reaffirm Treatment Options in CLL

Heinz-Josef Lenz, MD, FACP, about the prognostic and predictive value of HER2 gene expression for patients with KRAS wild-type metastatic colorectal cancer (mCRC). Lenz is a professor in the Department of Medicine and the Department of Preventive Medicine in the Division of Oncology at the University of Southern California (USC) Keck School of Medicine in Los Angeles. He also serves as the associate director of Clinical Research, chair of the Gastrointestinal Oncology Program, and co-director of the Colorectal Center at the USC Norris Comprehensive Cancer Center
June 3rd 2024

Lenz Discusses the Prognostic and Predictive Value of HER2 Gene Expression in KRAS Wild-Type mCRC

Angelos Stergiou, MD, ScD hc
June 10th 2024

CDK9 Inhibitor SLS009 Displays Activity in Relapsed/Refractory AML

D. Ross Camidge, MD, PhD; B.J. Rimel, MD, assistant professor, obstetrics and gynecology, Cedars-Sinai, medical director, Cancer Clinical Trials Office, Cedars-Sinai Cancer Institute, health sciences associate clinical professor, Department of Obstetrics and Gynecology, University of California, Los Angeles
April 15th 2024

Camidge and Rimel on the Importance of Cultivating Inclusive Gynecologic Oncology Practices

Eunice S. Wang, MD
June 6th 2024

Wang Expands on the Continued Investigation of Targeted Therapies in Relapsed/Refractory AML

Mark Frattini, MD, PhD
June 5th 2024

UCART22 Earns Orphan Drug Designation for Acute Lymphoblastic Leukemia in Europe